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ABSTRACT
Prediction of the biological effect of missense
substitutions has become important because they
are often observed in known or candidate disease
susceptibility genes. In this paper, we carried out
a 3-step analysis of 1514 missense substitutions
in the DNA-binding domain (DBD) of TP53, the most
frequently mutated gene in human cancers. First, we
calculated two types of conservation scores based
on a TP53 multiple sequence alignment (MSA) for
each substitution: (i) Grantham Variation (GV),
which measures the degree of biochemical variation
among amino acids found at a given position in the
MSA; (ii) Grantham Deviation (GD), which reflects
the ‘biochemical distance’ of the mutant amino acid
from the observed amino acid at a particular position
(given by GV). Second, we used a method that com-
bines GV and GD scores, Align-GVGD, to predict
the transactivation activity of each missense substi-
tution. We compared our predictions against experi-
mentally measured transactivation activity (yeast
assays)toevaluatetheiraccuracy.Finally,thepredic-
tion results were compared with those obtained by
the program Sorting Intolerant from Tolerant (SIFT)
and Dayhoff’s classification. Our predictions yielded
high prediction accuracy for mutants showing a
loss of transactivation ( 88% specificity) with
lower prediction accuracy for mutants with trans-
activation similar to that of the wild-type (67.9 to
71.2% sensitivity). Align-GVGD results were compar-
abletoSIFT(88.3to90.6%and67.4to70.3%specificity
and sensitivity, respectively) and outperformed
Dayhoff’s classification (80 and 40.9% specificity
and sensitivity, respectively). These results further
demonstrate the utility of the Align-GVGD method,
which was previously applied to BRCA1. Align-
GVGD is available online at http://agvgd.iarc.fr.
INTRODUCTION
Analysis of mutations has become increasingly important
due to their association with various diseases (1,2). Of the
disease-associated variations present in the Human Gene
Mutation Database (HGMD, http://www.hgmd.cf.ac.uk/
hgmd0.html), the majority are single base substitutions that
result in an amino acid change (missense mutation). Speciﬁc
examples where high frequencies of missense mutations are
associated with disease include the tumor suppressor TP53 and
sporadic cancers (3), CFTR and cystic ﬁbrosis (4) and AVPR2
and neurogenic diabetes insipidus (http://www.medicine.
mcgill.ca/nephros/). Large collections of mutation data are
available via HGMD, the Human Genome Variation Society
(http://www.genomic.unimelb.edu.au/mdi/) and OMIM (5).
More speciﬁc to cancer, the Catalogue of Somatic Mutations
in Cancer (Cosmic) holds over 23000 mutations in
538 cancer-related genes (http://www.sanger.ac.uk/genetics/
CGP/cosmic/).
Annotations of mutation effects are rarely found in these
databases, mainly because mutagenesis experiments and func-
tional assays are labor-intensive and data accrual does not
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data. In many instances, the nature and scope of such func-
tional assays are still a matter of debate. To circumvent these
limitations, more and more computational methods are being
developed to predict the function of missense mutants and to
identify residues that have a signiﬁcant effect on maintaining
wild-type function. Different approaches have been explored,
including sequence-based methods (6,7), structure-based
algorithms (8–12) and a combination of both (13–15).
The use of multiple sequence alignments (MSAs) to align
either closely related sequences, distantly related sequences or
both, have highlighted two major trends that are unique to
disease-associated mutations. First, differences in biochemical
properties between mutant and wild-type amino acids are
larger for disease-associated mutations than for neutral muta-
tions(16).This trendexistsbecause largebiochemical changes
between mutant and wild-type are more likely to alter the
structure and may hence change the function of the protein,
explaining why such changes are generally not tolerated
during natural selection. Second, mutations associated with
disease tend to be located at residue positions that are highly
conserved across species (17). In this sense, amino acids that
are conserved across species are more likely to have an
important structural or functional role. One popular method
for measuring biochemical distances between pairs of amino
acids is the Grantham Difference (18), which takes into
account the composition, polarity and volume of mutant
and wild-type amino acids.
In contrast to other tumor suppressor genes such as APC and
BRCA1, the majority of TP53 mutations are missense muta-
tions rather than truncating mutations. These missense muta-
tions are concentrated in the DNA-binding domain (DBD) of
the protein, comprising 194 amino acids. All mutations cited
in the literature are compiled in the IARC TP53 database (3),
which is the largest database of cancer associated mutations
available for a single gene. The p53 protein is a transcription
factor activated by various stress conditions, including DNA
damage, oncogene activation or hypoxia. P53 regulates the
transcription of several genes involved in DNA repair, cell
cycle checkpoints or apoptosis (19). Kato et al. (20) used a
yeast-based expression assay to measure the transactivation
activity of all possible p53 missense mutations, that can arise
due to a single nucleotide substitution, on eight different p53
response-elements (p53-RE) present in different p53 target-
genes: BAX, CDKN1 (WAF1), GADD45A, MDM2, P53AIP1,
PMAIP1 (NOXA), RRM2B (P53R2) and SFN (h1433S).
In this study, we have constructed a p53 protein MSA and
combined a conservation score (GV) with a measure of bio-
chemical difference between wild-type and mutant resi-
dues with respect to the alignment (GD). This extension of
the Grantham Difference, called Align-GVGD, has previously
been applied to BRCA1 and contributed to the clinical
categorization of eight previously unclassiﬁed missense muta-
tions (21). To demonstrate the signiﬁcance of the classiﬁca-
tions obtained with Align-GVGD, we have assessed them
against functional categories derived from experimental meas-
urements of transactivation activities of a subset of 1514 mis-
sense p53 mutants (20). Next, we have compared the resulting
prediction accuracies with those yielded by two well known
prediction methods. The ﬁrst is SIFT which calculates
normalized probabilities that speciﬁc substitutions would be
tolerated at a given position, and assigns the mutation effect
from a speciﬁc probabilities cutoff value (13,14). The second
is based on Dayhoff’s relatedness odds matrix (22), which
gives the probability that a substitution will occur by chance
in a second sequence using the PAM matrix.
MATERIALS AND METHODS
MSA
The p53 protein MSA was constructed with 3D-Coffee (23),
a web-based tool for aligning multiple sequences, which
takes into account relevant protein structure(s) to improve
the alignment. The following nine sequences were used for
the MSA: Homo sapiens (spjP04637), Macaca mulatta
(monkey, spjP56424), Bos taurus (bovine, spjP67939),
Canis familiaris (dog, spjQ29537), Mus musculus (mouse,
spjP02340), Rattus norvegicus (rat, spjP10361), Gallus gallus
(chicken, spjP10360), Xenopus laevis (frog, trjP53_
XENOPUS), Brachydanio rerio (zebraﬁsh, spjP79734). The
X-ray solved structure of the DBD of human p53 [PDB (24) id
1tsr, chain B] was also input. All default parameters when
running 3D-Coffee were used with the exception of excluding
the Msap_pair option, which performs structural alignments
(only one PDB structure was used), and including the ‘Mclus-
talw_aln’, an option for MSA.
Align-GVGD, SIFT and Dayhoff’s classification
GV and GD calculations in the Align-GVGD program (21) are
an extension of the Grantham Difference, which takes into
account the composition (C), polarity (P) and volume (V)
of amino acids (18). Conceptually, each amino acid can be
plotted on a 3D graph, having C, P, V as the three axes, with
different weights(18) applied toeach axis. Allaminoacidsata
given position in the MSA then form a cloud of points when
plotted. This cloud of points can be enclosed within a box, the
coordinates of which are deﬁned by the minimum and max-
imum values of C, P, V, for the observed amino acids. GV is
computed as the Euclidian length of the main diagonal of
the box. GV is thus a measure of the amount of observed
biochemical variation in a particular position in the alignment.
Next, the GD is calculated by plotting a given mutation on
the composition-polarity-volume graph, and measuring the
Euclidian distance between that mutation and the closest
point on the GV box. If the substitution lies within the box,
then GD ¼ 0. Otherwise, GD is greater than 0. GD is thus a
measure of the biochemical difference between the mutant and
the observed variation at that position according to the MSA.
The freely available web-based tool SIFT (http://blocks.
fhcrc.org/sift/SIFT.html) (13) was used with default settings
and the MSA obtained by 3D-Coffee as input. SIFT calculates
the probabilities of having an amino acid at a speciﬁc position
relative to the most frequent amino acid at that position. A
cutoff for these probabilities is used to classify the mutations
as tolerated and non-tolerated.
Mutants were classiﬁed according to Dayhoff’s substitution
matrix. The Dayhoff matrix highlights groups of amino acids
with common chemical and physical properties. The following
groups derived from the log odds ratio of the 250 PAM matrix
were used (22): (V,L,I,M), (R,K,H), (D,E,N,Q), (F,Y,W), (C),
1318 Nucleic Acids Research, 2006, Vol. 34, No. 5(A,S,T,G,P). When the mutant and wild-type amino acid fall
within a group, the mutation is considered conservative, if
they fall into different groups, the mutation is classiﬁed as
non-conservative.
P53 functional dataset
Kato et al. (20) measured the transactivation activity of all
possible missense mutations (2314) in p53 (codons 2 to 393),
resulting from a single nucleotide substitution, on eight dif-
ferent p53-RE derived from the following p53 target-genes
BAX,CDKN1,GADD45A,MDM2,P53AIP1,PMAIP1,RRM2B
and SFN. The transactivation activity of each mutant on each
p53-RE was expressed as a percentage of the transactivation
activity of the wild-type protein on the corresponding p53-RE.
Mutants that showed variations in transactivation activity
depending on the p53-RE were disregarded in our analysis
because of their ambiguous overall activity. A subset of 1514
mutants, showing a similar activity across all eight promoters,
was considered where mutants with percent activity below 45%
on all promoters were categorized as non-functional (446
mutants), and those with percent activity above 45% and
below 200% on all promoters were classiﬁed as functional
(1068 mutants). We refer to these mutants as ‘consistent
mutants’ (listed in Supplementary Table S1). In addition, muta-
tions at codon 72 were omitted from further analysis due to the
uncertainty of the wild-type amino acid at that position.
RESULTS
GV values were calculated for amino acid positions 2 to 393
(except codon 72) in p53, and GD values were computed for
the 1514 consistent missense mutations. GV values provide a
quantitative measure of the range of biochemical properties
for a given amino acid position, based on all residues found at
that position in a given MSA. GD values measure the distance
between the mutant amino acid (described by its polarity,
volume and composition) and the allowed variation as calcu-
lated by GV (see Materials and Methods for more details).
GV and GD values were calculated for four different MSA:
(i) Placental level: includes six placental mammal sequences,
(ii) Chicken level: includes seven sequences from placental
mammals to chicken, (iii) Frog level: includes eight sequences
from placental mammals to frog, (iv) Fish level: includes nine
sequences from placental mammals to ﬁsh. As more distantly
related sequences are added to the alignment, GV is expected
to increase for some residues. In addition, GD is expected to
decrease for many of the substitutions observed at residues
where GV increases.
Correlations between GV, mutation frequencies and
structural features
In this analysis, GV were calculated separately for all four
MSAs. The MSA of p53 using all sequences (human, monkey,
bovine, dog, mouse, rat, chicken, frog and zebraﬁsh) with the
corresponding GV values is shown in Figure 1. Positions with
aG V ¼ 0 (highlighted in green) have the same amino
acid across all species and are thus invariant. A total of 126
‘invariant’ residues out of 391 (32%) were found. Seven fully
conserved regions (with at least four positions in a row with
GV ¼ 0) were identiﬁed and include the following residue
positions: 117–122, 175–181, 196–200, 213–216, 218–221,
237–254 and 270–282. These regions lie within the DBD of
p53 and are consistent with previously identiﬁed conservation
domain (25).
GV values were directly compared with frequencies of
mutations found in cancers (data extracted from the IARC
TP53 database, http://www-p53.iarc.fr/). These frequencies
measure the association of a mutation with cancer, such
that positions with high frequencies are often observed in
cancer, making them likely to contribute to cancer develop-
ment. Figure 2 depicts the distribution of these frequencies at
each position in the p53 DBD with the corresponding GV
values. The graphs show an overall correlation between posi-
tions that are mutated at high frequency and those that have a
low GV, indicating that substitutions at positions that are
highly conserved are strongly selected for during tumorigen-
esis. This isparticularly true inareas ofp53 that contain the so-
called ‘mutation hotspots’ (residues 171–181, 237–258 and
270–282). However, not all conserved residues were fre-
quently mutated, as is shown by the low mutation frequencies
at residues 117–122 and 125–127. In addition, some areas of
relatively low conservation appear to contain minor mutation
hotspots, such as residues 157 and 158.
The GV values were mapped on to the 3D structure of
the DBD of p53 (26), comprising residues 96 to 289
(Figure 3). Invariant positions have GV ¼ 0 (red), conserved
positions have GV < 61.3 (orange) and for variable positions
GV > 61.3 (grey). Thevalue61.3 correspondstothe variation
across the polar amino acid set Asp, Asn, Glu and Gln. It was
arbitrarily chosen as the greatest level of amino acid variation
within a single position that one might consider ‘conservative
substitution’.Importantly,theﬁgure showsthatlowGVvalues
(less than 61.3) tend toconcentrate in the area ofDNA-binding
residues, which contains the majority of hotspot mutations
(27). Some correlations between structural features of residues
and their GV values are worth noting. First, the residues
involved in the zinc-binding domain, Cys176, His179,
Cys238 and Cys242 are all highly conserved positions (the
zinc isshownasa grey sphereinthe ﬁgure).Those residuesare
essential for zinc-binding and maintaining the structure.
Second, all residues involved in DNA-binding are highly
conserved: out of 14 residues, GV ¼ 0 for 13 positions and
GV ¼ 26 for 1 position (residue 283). Those residues are
functionally important as they either directly bind DNA
or help maintain the proper conformation to allow DNA-
binding. Third, most positions in the hydrophobic core,
which are mainly responsible for maintaining the stability
of the protein, have a high frequency of mutations and low
GV values (less than or equal to 30.9, which is GV for the
non-polar amino acid set Leu, Ile, Met and Val). Previously,
eleven highly conserved positions have been identiﬁed in the
hydrophobic core (156–158, 205, 215, 220, 232, 258, 259 and
266) (28). Only Arg156 showed a high GV value of 227.4. This
high GV value is mainly due to the addition of the more dis-
tantly related sequences of chicken, frog and ﬁsh.
Predictions of transactivation activity using
Align-GVGD
All missense mutants in the p53 DBD were predicted as
neutral, deleterious, or unclassiﬁed using the following ﬁve
Nucleic Acids Research, 2006, Vol. 34, No. 5 1319Align-GVGD criteria:
(1) if GD ¼ 0: the composition, polarity and volume of the
mutant amino acid fall within observed range of variation
according to the alignment at that position so the mutant
is predicted as neutral;
(2) if(GV > 61.3)and(0 < GD < 61.3):thepositiontolerates
morethan ‘conservative’substitutionandthe composition,
polarity and volume of the mutant amino acid fall close to
the observed range of variation according to the alignment
at that position so the mutant is predicted as neutral;
(3) if(GV ¼ 0)and(GD > 0):thepositionofinterest isinvar-
iant (100% conservation) so any mutation at the position is
predicted as deleterious;
(4) if(0 < GV < 61.3)and(GD > 0):thereisasmallvariation
in amino acids at a given position (the residues encount-
ered are biochemically similar), yet the mutant amino acid
does not fall within that range of variation. The mutant is
predicted as deleterious;
(5) if the mutant does not fall in the previous categories, it is
unclassified.
Table 1 shows the distribution of the classiﬁcations derived
from Align-GVGD values using the four different MSA
described in the previous section. Our results show that add-
ing more distantly related sequences increased the number of
mutants predicted as neutral while the number of mutants
predicted as deleterious decreased. Because adding more
Figure 1. GV valuesand MSAconstructedusing 3D-coffee. GV values calculatedwiththe completeMSA (fishlevel) are shownforeach position in the alignment
(the numbering follows that of the human sequence). Areas of total conservation are shown in green.
1320 Nucleic Acids Research, 2006, Vol. 34, No. 5distantly related sequences to the MSA introduces more
sequence variability, mutants previously classiﬁed as deleteri-
ous may now fall into the neutral category or into the unclas-
siﬁed category (when GV and GD both exceed 61.3).
These predictions were directly compared with trans-
activation categories derived from results of experimental
assays performed in yeast (20) on 1514 ‘consistent mutants’
(see Materials and Methods). Figure 4A shows the speciﬁcity
(ratio of correctly predicted deleterious mutants versus the
total number of observed non-functional mutants) and sen-
sitivity (ratio of correctly predicted neutral mutants versus
the total number of observed functional mutants) of the pre-
dictions obtained for each MSA on the ‘consistent’ mutants.
The results show three major trends. First, the prediction
accuracies for deleterious mutants are high (high speciﬁcity)
while they are lower for neutral mutants (low sensitivity).
Second, the addition of more distantly related species
increases the sensitivity. Because adding more divergent
sequences to the MSA increases sequence variability in the
alignment, GV for many of the positions increases, and this
will in turn decrease the GD for certain mutants (a mutated
residue is more likely to ﬁt in a larger allowable variation at
a given position). Third, adding more sequences does not
notably decrease the speciﬁcity. This important observation
suggests that the addition of more distantly related sequences
is essential for more accurate predictions of transactivation
activity.
To evaluate the efﬁcacy of our predictions, predictive
values (PV) for deleterious (percent of mutations predicted
as deleterious that are observed non-functional) and neutral
predictions (percent of mutations predicted as neutral that are
observed functional) were calculated (Figure 4B). The ﬁgure
demonstrates that when Align-GVGD predicts mutants as
neutral, about 95% actually are functional, according to the
transactivation activities. On the other hand, when Align-
GVGD predicts mutants as deleterious, 61.7 to 64.6% are
actually non-functional. As more divergent sequences are
added to the MSA, the predictive value for predicted deleteri-
ous mutants increases while the predictive value for the
predictive neutral mutants remains nearly constant.
Predictions of transactivation activity using SIFT and
Dayhoff’s classification
SIFT was used to classify the p53 missense mutants using our
four different MSA as input. The categories obtained with
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include residues 117–122 and 125–127, which describe areas with low GV values (high conservation) but very low mutation frequency.
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tion categories as performed above with Align-GVGD.
Mutants classiﬁed as non tolerant by SIFT were expected to
be non-functional while those classiﬁed as tolerant were
expected to be functional. The speciﬁcity/sensitivity and PV
of the SIFT predictions are shown in Figure 5A and B, respect-
ively. In comparison with Align-GVGD predictions, SIFT
yielded similar speciﬁcity (88.3 to 90.6% versus  88% for
Align-GVGD) and similar sensitivity values (67.4 to 70.3%
versus 67.9 to 71.2% for Align-GVGD). In addition, although
the PV for the predicted tolerant/neutral mutants are very
similar (about 95%), those for intolerant/deleterious mutants
are higher for Align-GVGD (61.7 to 64.6%) than for SIFT
(53.4 to 55.9%).
Finally, categories based on Dayhoff’s conservation
rules (see Materials and Methods) were compared with
transactivation activity. Table 2 shows the resulting predic-
tions when associating conservative mutations with
non-functional mutants and non-conservative mutations
with functional mutants. The sensitivity/speciﬁcity and PV
are lower compared to those obtained with either the Align-
GVGD or SIFT approaches.
Align-GVGD as a freely available and web-based
software
A web interface has been developed to access the Align-
GVGD program, written in Perl (available at http://agvgd.
iarc.fr). As input, users must provide their own MSA and a
list of mutations either by uploading the appropriate ﬁles or
by copying/pasting. Both input ﬁles must be simple text ﬁles
(Word documents are not recommended) and the MSA must
be in FASTA format. The program will then output a table
containing GV and GD for all mutations given in the input ﬁle,
along with functional predictions: deleterious 1 (GV ¼ 0 and
GD > 0), deleterious 2 (0 < GV < 61.3 and GD > 0), neutral
1 (GD ¼ 0), neutral 2 (GV > 61.3 and 0 < GD < 61.3) and
unclassiﬁed. Users may download the results in a tab delimited
simple text ﬁle which may easily be imported into Excel for
AB
Figure 4. Prediction of experimentally measured transactivation activity by the Align-GVGD scoring method. (A) The specificity (ratio of correctly predicted
deleterious mutants versus the total number of observed non-functional mutants) and sensitivity (ratio of correctly predicted neutral mutants versus the total
number of observed functional mutants) of the predictions are shown for four different MSA. As more divergent sequences are added to the MSA, the predictions
improveandshowasubstantialincreaseinspecificitywithonlyacomparativelyslightdecreaseinsensitivity.(B)PVforpredicteddeleteriousandpredictedneutral
mutants at the four sequence levels are depicted. While the PV for predicted neutral mutants is relatively unchanged, the PV for predicted deleterious mutants
increases when more divergent sequences are added to the MSA.
Table 1. Distribution of classifications made by Align-GVGD
Eutherian
a Chicken
b Frog
c Fish
d
Neutral 765 766 794 800
Deleterious 637 637 608 607
Unclassified 112 111 112 107
aMSA used includes all sequences but chicken, frog and fish.
bMSA used includes all sequences but chicken and frog.
cMSA used includes all sequences but frog.
dMSA used includes all sequences.
Figure 3. Representation of the DBD of p53 (PDB ID 1tsr, chain B), color-
coded by GV values with the following cutoffs: GV ¼ 0, red; 0 < GV < 61.3,
orange; GV > 61.3, grey. The figure shows that areas of high conservation
(red) involveresiduesfoundinDBDand zinc-bindingmotif.Otherareasofthe
protein do not show a particular conservation trend.
1322 Nucleic Acids Research, 2006, Vol. 34, No. 5further analysis. The program uses all sequences in the align-
ment when performing the calculations. Error messages
appear when the MSA is not in the correct format or when
unknown amino acid letter codes (other then the 20 letters for
the naturally occurring amino acids and the gap symbol‘-’) are
found in the MSA or list of mutations.
DISCUSSION
Previous studies have found a strong correlation between
highly conserved residues and intolerance of mutations,
which are likely to cause disease (16,17). The majority of
mutations associated with disease show larger biochemical
differences between mutant and wild-type amino acids than
between amino acids observed in the MSA for a given posi-
tion (17). These observations provide the basis for our Align-
GVGD approach, which considers both the biochemical
variability for a position in the MSA and the distance from
a mutant amino acid to the observed variability. Application
of the Align-GVGD method to p53, which has the largest
mutation dataset available on a single gene, along with a
comprehensive dataset of transactivation activities measured
in experimental yeast assays, provides an opportunity to
further assess the signiﬁcance of the correlation between
conservation and functional effect of mutations.
Validation of our MSA and GV values was performed by
comparing GV values with conservation and structural fea-
tures previously reported.Seven fully conserved regions (117–
122, 175–181, 196–200, 213–216, 218–221, 237–254 and
270–282) with GV ¼ 0 were found, consistent with previ-
ously identiﬁed conserved clusters (28,29). To validate our
MSA and GV values, we compared our correlations between
conservation and structural features of residues with those
previously reported (30) and concordantly found that residues
in the zinc- and DNA-binding motifs are highly conserved.
We found that GV values at each position in p53 strongly
correlated with the frequencies of mutants observed in
human cancer as reported in the IARC TP53 database (3).
In the DBD, low GV values (less than 42.8) were observed
for the vast majority of residues located in the previously
identiﬁed ﬁve ‘mutation hotspot’ regions, including residues
132–143, 151–159, 172–179, 237–249 and 272–286 (29).
A divergence between GV values and mutation frequency
was noted for the region of the p53 DBD comprising residues
117 to 122. This cluster corresponds to a conserved portion of
the L1 loop that directly binds tothe major groove of the DNA.
These residues have low GV values but are rarely found
mutated in human cancer. It is thus likely that substitution
at these residues does not affect p53 function in a way com-
patible with loss of tumor suppressive activities. Indeed, stud-
ies by Resnick and colleagues (31) have found that mutations
in this area often resulted in mutant proteins with increased
transactivation activities (called ‘supertrans mutants’). Such
mutants would be counter-selected, and therefore very rare, in
human cancer.
Functional predictions based on appropriate GV and GD
cutoff values were then compared with the experimentally
measured transactivation activities. We accurately predicted
the activity of up to 88.1% deleterious mutants (unable to
transactivate) and 71.2% neutral mutants (able to transactiv-
ate). The accurate prediction of neutral mutants increased as
more distantly related sequences were added to the MSA,
while only slightly decreasing the accurate prediction of
deleterious mutants. The Align-GVGD values are thus highly
dependant on the MSA. Previous studies suggest that using
both closely and distantly related sequences in appropriate
proportion is most suitable for accurate construction of
MSA (16,32). This is because relying mainly on closely
related sequences will result in an apparent lack of sequence
variation due to little divergence between the individual
sequences. On the other hand, using sequences that are too
divergent increases the risk of including a related sequence
that codes for a protein that has a different function. In this
case, the number of functionally constrained sites will be
under-estimated. Because the choice of sequences to use in
an MSA is highly dependent on the protein studied, it is best
to make a systematic comparison between alignments of
AB
Figure 5. Prediction of experimentally measured transactivation activity using SIFT software (13) and four different MSA as input. (A) The specificity and
sensitivity, and (B) PV of the predictions are shown. No noticeable correlation is observed between the addition of more divergent sequences in the MSA and
the diagnostic values.
Table 2. Transactivation prediction results using Dayhoff conservation cat-
egories
Specificity 80
Sensitivity 40.9
PV for predicted deleterious 36.1
PV for predicted neutral 83.1
Nucleic Acids Research, 2006, Vol. 34, No. 5 1323increasing divergence in order to ﬁnd an optimal combination
of sensitivity and speciﬁcity.
We found that our predictions, using Align-GVGD, were
similar to those obtained from SIFT, and better than those
obtained using Dayhoff’s conservation rules. Although SIFT
attempts to classify all mutants as either tolerated or not
tolerated, Align-GVGD allows a third ‘unclassiﬁed mutants’
category which probably leads to a higher level of certainty in
the predicted effect of categorized mutants. Indeed, the biggest
performance difference between Align-GVGD and SIFT was
in the predictive value for deleterious substitutions [PV(D)].
For Align-GVGD, PV(D) ranged from 61.7 to 64.6% and the
highest value resulted from the complete alignment, whereas,
for SIFT, PV(D) ranged from 53.4 to 55.9% and depended
little on the alignment. Thus both programs over-predict false
deleterious substitutions, which is the type of false-positive
error that we would most likely to avoid. False-positive pre-
diction of deleterious substitutions should be mostly due to
two sources of error. The ﬁrst is assay-based: p53 is involved
in numerous pathways and has biochemical activities other
than DNA-binding and transcriptional activation, thus some
of the substitutions are likely to affect functions not measured
by the transcriptional reporter assay. But in silico prediction
methods have intrinsic false-positive error rates; e.g. SIFT is
reportedtohave a‘weighted false-positiveerrorrate’ of 20%
(14). As assay-based false positives should affect both
algorithms equally, the PV(D) difference between the two
algorithms should reﬂect a small Align-GVGD advantage
towards prediction of deleterious substitutions. Interestingly,
 87% of mutants unclassiﬁed by Align-GVGD are experi-
mentally functional. This implies that some mutants (93 out
of 1514) may have high GV and/or GD (both higher than 61.3)
while being experimentally functional. These mutants then
show a substantial variation across species and/or the mutant
residue is substantially different from the residues observed at
the respective position. This counter-intuitive observation
demonstrates the limitations of using solely sequence informa-
tion to make predictions.
One advantage of SIFT over our Align-GVGD method is
that SIFT allows automatic generation of an MSA, either from
the input of one sequence (of the species under study), or from
the input of all sequences to be included in the alignment.
However, Align-GVGD shows a stronger dependency on the
input MSA than does SIFT, suggesting that Align-GVGD
predictions may be improved with a more informative MSA
as input.
A major incentive for using Align-GVGD is that the
program provides quantitative measures of the range of bio-
chemical variation of the amino acids present at the position
of a missense substitution (GV) and the distance between
the missense substitution and that range of variation (GD),
and these measures are on the same scale as the original
Grantham Difference. One can thus easily trace back the
features of amino acids and help explain the reasons for
strong or weak correlations between GV, GD and function.
The current set of Align-GVGD cutoff values are based on
biophysical reasoning rather than optimization over a dataset.
Furthermore, this approach does not require entire sequences
or entire structures as input. Although the structure may be used
to construct the MSA, as was done in this study, it is not
mandatory.
Several modiﬁcations may be applied to further improve
the predictions. First, the ‘consistent mutants’ could be used as
a training set to improve the cutoff values for GV and GD.
However, the a priori rules that are currently used in Align-
GVGD present an advantage in that the cutoffs are not depend-
ant on functional data, which are often neither comprehensive
nor fully representative of the range of activities displayed by
a protein. Second, adding another distantly related sequence
may further improve the results. Provided the trend seen in
Figure 4A continues, it is likely that the sensitivity will
increase. Moreover, the speciﬁcity and sensitivity will likely
be closer to converging, indicating that the algorithm may
accurately classify as many neutral as deleterious mutants.
However, one must ascertain that the most distantly related
sequence still has the same function as human p53. Over the
last few years, the release of tunicate and sea urchin genome
sequences in addition to a series of vertebrate sequences
should lead to many more gene model and cDNA sequences
of human gene orthologs, thereby leading to more appropri-
ately informative MSA. With these new sequences and the
simplicity and web-based availability of softwares such as
Align-GVGD and SIFT, the accuracies of functional predic-
tions of missense substitutions will undoubtedly increase.
Overall, we show that the GV values for each residue in
p53 correlate well with the frequencies of mutations in human
cancers extracted from the IARC TP53 database. Using pre-
deﬁned Align-GVGD cutoff values, we accurately predicted
the transactivation activity of up to 88.1% of deleterious and
71.2% of neutral mutants, which have a similar transactiva-
tion activity across all p53-REs tested. The addition of more
distantly related sequences increases the accuracy of predic-
tions for neutral mutants substantially while only slightly
decreasing the accuracy of predictions for deleterious mutants.
The simplicity and web-based availability of Align-GVGD
will allow functional classiﬁcation of missense mutants for
any genes with sufﬁcient sequences available.
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